Integrated Treatment and Prevention for People Who Inject Drugs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1281 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-04

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the feasibility of a future trial that will assess whether an integrated intervention combining psychosocial counseling and supported referrals for antiretroviral therapy (ART) at any CD4 cell count and substance use treatment for HIV-infected people who inject drugs (PWID) will reduce HIV transmission to HIV-uninfected injection partners, as compared to routine care dictated by national guidelines for HIV-infected PWID.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Behavioral Intervention Trial for HIV-infected Injection Drug Users

NCT00146445

HIV

COMPLETED PHASE2/PHASE3

A Study of Peer Education to Prevent HIV Transmission Among Injection Drug Users and Their HIV Risk Contacts

NCT00038688

HIV Infections

COMPLETED PHASE3

Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India

NCT05165810

HIV Infections

ACTIVE_NOT_RECRUITING NA

A Network & Dyad HIV Prevention Intervention for IDU's - 1

NCT00218335

HIV Hepatitis

COMPLETED PHASE2

Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation

NCT06103370

HIV Infections Substance Use Disorders Addiction +3 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-site, two-arm, randomized, vanguard study. Network units will consist of an HIV-infected index participant and his/her HIV-uninfected network injection partner(s). Network units will be randomized to the intervention or standard of care arms in a 1:3 ratio, stratified by site. To assess feasibility of the intervention, additional interviews will be conducted with study staff (systems navigators and counselors) and clinic-based stakeholders at each study site.

Approximately 500 Index participants and their partners will be enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Positive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Standard of Care

Group Type NO_INTERVENTION

No interventions assigned to this group

Integrated Intervention

Standard of care plus an integrated system of psychosocial counseling and systems navigation for HIV treatment and Substance Use treatment

Group Type EXPERIMENTAL

Integrated Intervention

Intervention Type BEHAVIORAL

systems navigation, psychosocial counseling

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Integrated Intervention

systems navigation, psychosocial counseling

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Index participants:

* Age 18-45 years at the Screening visit (age verification procedures will be defined in the Study Specific Procedures \[SSP\] Manual)
* Able to provide informed consent
* Active injection drug user, defined as self-report of: a) injecting drugs approximately two or more times per week for the past three months, and b) ability to identify the anatomical location of the most recent injection site, as determined by study staff
* Reports sharing needles/syringes or drug solutions at least once in the last month
* HIV-infected based on a study-defined testing algorithm (defined in the SSP Manual)
* Viral load ≥1,000 copies/mL at Screening
* Willing and able to identify, recruit, and have enrolled at least one HIV-uninfected network injection partner who is eligible for study participation according to the criteria below
* Have no plans to move outside the study area for at least one year after study enrollment
* Willing to participate in intervention activities, including regular phone contact

HIV uninfected injection partners:

* Age 18-45 years at the Screening visit (age verification procedures will be defined in the SSP Manual)
* Able to provide informed consent
* Active injection drug user, defined as: a) self-report of injecting drugs approximately two times per week for the past three months, and b) ability to identify the anatomical location of the most recent injection site, as determined by study staff
* Confirmed injection partner, using referral identification cards, of index participant within the past 1 month
* HIV-uninfected based on the study-defined testing algorithm\* (defined in the Study SSP Manual)
* Have no plans to move outside the study area for at least one year after study enrollment